CLSA Cohosts Congressional Briefing & Participates in Bio Fly-in

By Jenny Nieto 
April 21, 2019

CLSA Board Chairman Bill Newell, CEO of Sutro Biopharma

On April 3, 2019, CLSA cohosted a multi-state life sciences association bipartisan congressional briefing on “Life Sciences Innovation: From Research to Cures.” The event was convened in collaboration with Rep. Scott Peters (D-San Diego) and Rep. John Curtis (R-Utah). CLSA cohosted the event along with a dozen other state and regional life sciences associations, including San Diego-based Biocom, Healthcare Institute of New Jersey (HINJ), Life Sciences Pennsylvania, and Michigan Bio, as well as BioNJ, Bio Utah, Bio West Virginia, Colorado Bioscience Association, Delaware Bio, Indiana Medical Device Manufacturers Council (IMDMC), Massachusetts Bio, MassMEDIC, Medical Alley (Minn.), MedTech (N.Y.), and North Carolina Bio.

Rep. Scott Peters (D-San Diego)

The event’s expert panelists included: CLSA’s Board Chairman Bill Newell, CEO of Sutro Biopharma; James Baker, MD, Professor Emeritus of Internal Medicine Medical School and Biomedical Engineering at the University of Michigan; Brandi Simpson, CEO of Navigen, Inc.; and, Eric Gascho, Vice President of Policy and Government Affairs at National Health Council. The discussion was focused on the research and development process, the pathway to new medical breakthroughs and discoveries, the innovation ecosystem, and the risks to the continued advancement of global human health and future treatments and cures for some of the world’s most deadly diseases.

The following day, CLSA’s Washington, D.C.-based Federal Government Relations team and CEO Mike Guerra, CLSA member companies and several members of the CLSA Board of Directors participated in BIO’s annual legislative fly-in to advocate for life sciences innovation, investment, and job creation in California and the U.S. Over the course of the day, life sciences advocates for California participated in over 2 dozen meetings with California Members of Congress and Congressional staff.

Discussions were focused around the importance of ensuring the access to and affordability of innovative medicines, preserving the market-based reimbursement structure, supporting basic research and workforce development, encouraging renewal of the Pandemic and All-Hazards Preparedness Act (PAHPA) and proper funding of biodefense and pandemic preparedness priorities, and improving coverage and payment policies to encourage and reward innovation and value.

CLSA is proud to support and participate in opportunities to leverage the collective strength of national, state and regional life sciences associations across the country. Check out the buzz on our multi-state life sciences briefing at #Research2Cures and #ResearchMatters, and the BIO Fly-in at #BioFlyIn.

Questions? Please contact Jenny Nieto, CLSA’s Vice President of Federal Government Relations & Alliance Development (